Avita Medical, Inc. (RCEL) intrinsic value & 10-year financials
Avita Medical, Inc. (RCEL) has a Graham intrinsic value of AUD 46.50 per share. At AUD 13.04 on Oct 17, 2026, the stock trades 72% below that value. Over the last 10 fiscal years revenue grew 72.6% a year to AUD 70.9M, with an average return on invested capital of -1252.0%.
- Graham intrinsic value
- AUD 46.50
- Share price (Oct 17, 2026)
- AUD 13.04
- Price vs Graham value
- 72% below
- Market cap
- AUD 363.3M
- Revenue (FY2025)
- AUD 70.9M
- Revenue growth (10-yr CAGR)
- 72.6%
- ROIC (10-yr avg)
- -1252.0%
- Free cash flow (FY2025)
- -AUD 32.2M
RCEL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | AUD 70.9M | -AUD 48.6M | -AUD 1.74 | -AUD 32.2M | -60.0% | -158.2% |
| FY2024 | AUD 63.9M | -AUD 61.8M | -AUD 2.39 | -AUD 58.1M | -88.6% | -108.8% |
| FY2023 | AUD 50.1M | -AUD 35.4M | AUD 1.40 | -AUD 39.4M | -85.1% | -63.0% |
| FY2022 | AUD 34.4M | -AUD 26.7M | AUD 1.07 | -AUD 19.5M | -79.9% | -75.7% |
| FY2021 | AUD 29.2M | -AUD 26.6M | AUD 1.17 | -AUD 26.8M | -90.8% | -820.9% |
| FY2020 | AUD 14.3M | -AUD 42.0M | AUD 2.07 | -AUD 23.3M | -299.2% | -6285.6% |
| FY2019 | AUD 5.5M | -AUD 25.1M | AUD 1.56 | -AUD 20.3M | -466.4% | — |
| FY2018 | AUD 929.0K | -AUD 12.7M | AUD 1.37 | -AUD 13.3M | -1489.9% | — |
| FY2017 | AUD 901.4K | -AUD 11.5M | -AUD 1.72 | -AUD 9.0M | — | — |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in AUD.
Executive summary
AVITA Medical, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
AVITA Medical, Inc. has historically struggled to out-earn its cost of capital, averaging just -53.4% ROIC.
AVITA Medical, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, AVITA Medical, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $46.50 per share.